This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
4 Sep 2016

Hikma launches galantamine tablets in the US

Generic equivalents to Razadyne.

Hikma Pharmaceuticals has announced that its wholly owned US affiliate, West-Ward Pharmaceuticals has launched Galantamine Tablets in 4 mg, 8 mg, and 12 mg strengths, the generic equivalents to Razadyne. West-Ward’s Galantamine Tablets are indicated for the treatment of mild to moderate dementia in patients with Alzheimer’s disease.

According to IMS Health, US sales of Galantamine Tablets in 4 mg, 8 mg, and 12 mg strengths were approximately $8.45 million for the 12 months ending July 2016.

Said Darwazah, Chairman and CEO of Hikma, said: “We are very pleased to be launching this product from the West-Ward Columbus portfolio. We have an excellent pipeline of differentiated products and proven R&D, supply chain and operational capabilities that we expect will drive accelerated and sustainable future growth.”

Related News